Table 2 Incidence of ANKENT in non‐castrated and castrated B10.BR males, castrated B10.BR males with testosterone substitution, and in control and testosterone treated B10.BR females.
| No of mice | Treatment | No of ANKENT positive/total mice | Occurrence of ANKENT | % with ANKENT* |
|---|---|---|---|---|
| (months)* | ||||
| 104 Males | None | 9/104 | 4, 5.5, 5.5, 6.5, 7, 8, 9, 9, 12 | 8.7 |
| 93 Males | Castration | 0/93 | 0 | |
| 37 Males | Castration + Te | 3/37 | 6.5, 10, 11 | 8.1 |
| 30 Females | None | 0/30 | 0 | |
| 32 Females | Te | 0/32 | 0 |
*Significant difference in the incidence of ANKENT was found between the control males and castrated males (p<0.01), and between castrated males and castrated males injected with Te (p<0.01).
Te, testosterone.